technology
Allogeneic-Cell-Therapy
Where it's used
CAR-T cell therapy
A patient's own T cells are collected, engineered with a chimeric antigen receptor (CAR) using a lentiviral vector, expanded and re-infused to kill cancer — an approved one-time living-drug class spanning CD19 lymphoma/leukemia and BCMA multiple myeloma, now advancing toward off-the-shelf allogeneic products.
Stem cell therapy for autoimmune disease
Living mesenchymal stromal cells (MSC) or regulatory T cells (Treg) are infused to re-tolerise the immune system in autoimmune and inflammatory disease — an approved-asset class led by Mesoblast's Ryoncil for steroid-refractory GVHD and TiGenix's Alofisel for Crohn's fistula, with a deeper engineered-Treg pipeline for lupus, arthritis and aplastic anemia.